To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question

被引：0
|
作者：
Lukasik, Zuzanna [1 ,2 ]
Carron, Philippe [1 ,2 ]
Webers, Casper [3 ,4 ]
机构：
[1] Univ Ghent, Ghent Univ Hosp, Dept Internal Med & Pediat, Ghent, Belgium
[2] VIB Ctr Inflammat Res, Ghent, Belgium
[3] Maastricht Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Maastricht, Netherlands
[4] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands
来源：
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2023年 / 37卷 / 03期
关键词：
Axial spondyloarthritis; Tapering; Discontinuation; Remission; Therapy; Biological DMARD; SOCIETY CLASSIFICATION CRITERIA; ASAS-EULAR RECOMMENDATIONS; ANKYLOSING-SPONDYLITIS; PSORIATIC-ARTHRITIS; DOSE REDUCTION; PERIPHERAL SPONDYLOARTHRITIS; RHEUMATOID-ARTHRITIS; NON-INFERIORITY; TNF-INHIBITORS; DOUBLE-BLIND;
D O I：
10.1016/j.berh.2023.101869
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and discontinuation of bDMARDs in patients with axSpA. We discuss the scientific rationale and benefits of tapering, identify advice to apply tapering in current practice, and delineate aspects to be investigated in future research. (c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页数：17
相关论文
共 50 条
  • [21] Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement
    Simone, Davide
    Nowik, Marcin
    Gremese, Elisa
    Ferraccioli, Gianfranco F.
    JOURNAL OF RHEUMATOLOGY, 2015, 42 : 65 - 69
  • [22] Combinations of conventional disease-modifying antirheumatic drugs
    O'Dell, JR
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2001, 27 (02) : 415 - 426
  • [23] Moderne AntirheumatikaModern disease-modifying antirheumatic drugs
    U. Müller-Ladner
    K. Richter
    I.H. Tarner
    Der Internist, 2015, 56 : 307 - 314
  • [24] THE RELATIVE TOXICITY OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    FRIES, JF
    WILLIAMS, CA
    RAMEY, D
    BLOCH, DA
    ARTHRITIS AND RHEUMATISM, 1993, 36 (03): : 297 - 306
  • [25] RATIONAL USE OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    FURST, DE
    DRUGS, 1990, 39 (01) : 19 - 37
  • [26] Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
    Rudwaleit, Martin
    Morup, Michael
    Humphries, Brittany
    Zannat, Noor-E
    Willems, Damon
    Taieb, Vanessa
    Boonen, Annelies
    RMD OPEN, 2023, 9 (04):
  • [27] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS - STRATEGIES FOR SCREENING
    BOWEN, JG
    CROSSLEY, MJ
    HUNNEYBALL, IM
    PHARMACOLOGY & THERAPEUTICS, 1992, 56 (03) : 287 - 306
  • [28] Disease-modifying antirheumatic drugs and organising pneumonia
    Faisal, Mohamed
    Roslan, Asyraf
    Abeed, Nik Nuratiqah Nik
    Ban Yu-Lin, Andrea
    BMJ CASE REPORTS, 2021, 14 (01)
  • [29] Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study
    Qian He
    Jia-qi Chen
    Xin-bo Yu
    Jia-he Liao
    Zi-wei Huang
    Jian-ying Yang
    Tzu-Hua Wu
    Wei-jiang Song
    Jing Luo
    Qing-wen Tao
    Clinical Rheumatology, 2023, 42 : 1999 - 2011
  • [30] Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study
    He, Qian
    Chen, Jia-qi
    Yu, Xin-bo
    Liao, Jia-he
    Huang, Zi-wei
    Yang, Jian-ying
    Wu, Tzu-Hua
    Song, Wei-jiang
    Luo, Jing
    Tao, Qing-wen
    CLINICAL RHEUMATOLOGY, 2023, 42 (08) : 1999 - 2011
12345